ASP0367 is being investigated to determine whether it can turn on the PPAR delta (δ) pathway. The PPAR–δ pathway regulates mitochondria by turning on different genes in the cell. When the pathway is on, the mitochondria use fatty acids more often and more mitochondria are made. Using more fatty acids for energy results in increased energy production. ASP0367 is an oral investigational drug and is not currently approved by any regulatory bodies.
A preclinical study was conducted in 2017 and phase 1 study for healthy volunteers was completed in 2018. A Phase 1b study is now actively recruiting.
This program is sponsored by Astellas Pharma Inc..
ACTIVELY RECRUITING | A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) |
JUNE 2021 | Astellas Pharma Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
MAY 2021 | Webinar: ASP0367 Development Program UpdateAstellas Pharma joined PPMD for a webinar on May 19, 2021 to provide an update on the company’s ASP0367 development program. |
JULY 2020 | Astellas Pharma Presents at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library |
JUNE 2018 | Mitobridge Presents at the PPMD 2017 Annual Conference |
